Dr Tahrani provides a valuable insight into the latest developments in obesity management in type 2 diabetes.
1. Can weight loss cure type 2 diabetes (T2D)? (0:11)
2. Has any particular weight loss method been more successful than others at reducing hyperglycaemia in T2D? (0:51)
3. Will low-calorie diets or exercise will ever be prescribed as alternatives to pharmacological or surgical interventions for the management of obesity in T2D? (2:19)
4. What are your highlights of EASD 2018? (3:24)
Speaker’s disclosures: Dr Abd Tahrani has received fees, grants and honoraria from Novo Nordisk, AstraZeneca, BMI and Sanofi.
Filmed at the European Association for the Study of Diabetes (EASD) annual meeting, Berlin, Germany, 2018
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!